Answers are grounded in this paper and cite their sources.
The paper reviews emerging pharmacological strategies to improve the treatment of STEMI, focusing on novel fibrinolytics and adjunctive antithrombotic therapies.
Fibrinolytic therapy has long been an important component of the treatment of patients with ST-elevation myocardial infarction (STEMI). Several new treatment strategies are currently being developed to improve the treatment of STEMI. These strategies include the development of new fibrinolytic agents that possess longer half-lives or increased fibrin specificity as compared with streptokinase or alteplase; combining fibrinolytic therapy with recently developed antiplatelet medications; and substitution of low-molecular weight heparins or other newer thrombin inhibitors for unfractionated heparin to improve the safety, convenience and efficacy of antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Werf et al. (2002) conducted a review in ST-elevation myocardial infarction (STEMI). New treatment strategies (new fibrinolytic agents, antiplatelet medications, low-molecular weight heparins) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: